4//SEC Filing
PAUL STEVEN M 4
Accession 0001193125-25-203537
CIK 0002012593other
Filed
Sep 14, 8:00 PM ET
Accepted
Sep 15, 4:05 PM ET
Size
7.4 KB
Accession
0001193125-25-203537
Insider Transaction Report
Form 4
PAUL STEVEN M
Director
Transactions
- Purchase
Common Stock
2025-09-12$24.50/sh+28,284$692,947→ 28,284 total(indirect: By LLC) - Purchase
Common Stock
2025-09-12$24.97/sh+13,382$334,165→ 41,666 total(indirect: By LLC)
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $23.90 to $24.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected.
- [F2]Shares held by Paul Capital Strategy III Fund LLC. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any.
- [F3]The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $24.90 to $25.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected.
Documents
Issuer
Rapport Therapeutics, Inc.
CIK 0002012593
Entity typeother
Related Parties
1- filerCIK 0001237564
Filing Metadata
- Form type
- 4
- Filed
- Sep 14, 8:00 PM ET
- Accepted
- Sep 15, 4:05 PM ET
- Size
- 7.4 KB